FreeStyle Libre 3: Welcome to the U.S.

Abbott takes diabetes management to the next level in the U.S. with its next-gen continuous glucose monitor.

Strategy and Strength|May.31, 2022

Smaller,  greener and more accurate. Scratch that. Most accurate.1, 2, 3

The world’s leading continuous glucose monitor (CGM) has extended its lead with this next-generation technology — the FreeStyle Libre 3 system— now cleared by the U.S. Food and Drug Administration for people ages 4 and up in the U.S. living with diabetes.

The size of just two stacked U.S. pennies, Abbott’s FreeStyle Libre 3 system features the world’s smallest, thinnest1 and most accurate14-day glucose sensor on the market. The system automatically sends real-time, minute-by-minute glucose readings to a compatible smartphone4 without scanning, has the strongest Bluetooth range of any CGM,5,6,7 and uses significantly less plastic than previous versions.5

This technology also:

  • Offers optional glucose alarms.4,6

  • Provides glucose history and trend arrows with a quick look at your phone.4

  • Integrates with LibreLinkUp(smartphone app) and LibreView (cloud-based data system), enabling caregivers and healthcare professionals to remotely monitor loved ones and patients as needed.9, 10

And all of this for the same price as the FreeStyle Libre 2 system.

Translation: Managing diabetes just got even more discreet,11 seamless,6 reliable6 and better for the environment.11

“The FreeStyle Libre 3 system is a game changer for the millions of people living with diabetes. It’s a direct result of listening to our customers and giving them the innovation and sensing technology they’ve been looking for,” said Jared Watkin, senior vice president, Diabetes Care, Abbott.

Market Standout
The global CGM market, valued at more than $7 billion,12 provides a significant expansion opportunity for Abbott, the market leader with approximately 4 million FreeStyle Libre users worldwide.13

Consider that 537 million adults worldwide are living with diabetes and this number is projected to balloon 37.2% to 783 million people by 2045. In the U.S. alone, diabetes is the most common chronic condition with more than 133 million people (nearly half the population) living with diabetes or prediabetes.

Additionally, the CGM market is evolving beyond traditional users of the technology — people with type 1 diabetes who use an insulin pump — to also include those with type 1 and type 2 diabetes who don’t take insulin. This is an opportunity to help a broader group of people and to expand in this market.

“We continue to disrupt the notion that CGMs have to sacrifice quality or accuracy for affordability,” said Watkin. “Access to breakthrough diabetes technologies should not be out of reach for the people who can benefit most from them.”

Learn more about the FreeStyle Libre 3 system and its FDA clearance.


1Among patient-applied sensors

2Compared to previous FreeStyle Libre systems.

3FreeStyle Libre 3’s User Manual.

4The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView.

5Data on file. Abbott Diabetes Care.

6Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.

7Based on the signal strength in Dexcom G6 CGM User Guide and Medtronic Guardian Connect System User Guide.

8The LibreLinkUp app is only compatible with certain mobile device and operating systems. Please check for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. LibreLinkUp is not intended to be used for dosing decisions. The user should follow instructions on the continuous glucose monitoring system. LibreLinkUp is not intended to replace self-monitoring practices as advised by a physician. The user’s device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.

9LibreView is ISO27001/27018/27701 certified and HITRUST CSF Certified.

10The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

11Data on file, Abbott Diabetes Care.

12Data on file, Abbott Investor Relations.

13Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre portfolio compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.



Failure to use FreeStyle Libre 3 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or for safety info.